/
Oncology
Resectable Hepatocellular Carcinoma
7
Pipeline Programs↗
6
Active Trials↗
6
Companies Involved↗
Resectable Hepatocellular Carcinoma is an early-stage landscape with 7 programs across 6 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical2
Phase 14
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
71%
Monoclonal antibody
5 of 7 classified programs — the dominant modality here.
Monoclonal antibody leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.
Analysis
Trial Status
6
clinical trials
Active, not recruiting2 · 33%
Recruiting2 · 33%
Not yet recruiting2 · 33%
Clinical Trials
Trial Activity
6 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)